KRAS and non-small cell lung carcinoma: Preclinical studies on NSCLC cells resistant to TKIs have reported two types of NRAS mutations—namely E63K, a novel single base pair substation, and a gain of copy number of wild type (wt) NRAS or wt KRAS [97].